Want to see USNA full AI Analyst Report?
Top Page
USANA Health
(NYSE:USNA)
Select Model
Select Model
Rating:60Neutral
Price Target:
$24.00
▲(5.08% Upside)
Action:Reiterated
Date:08/05/26
The score is primarily held back by weakened profitability and very weak free cash flow despite a strong, low-debt balance sheet. Technically, the setup is supportive with price above key moving averages and positive momentum indicators, but valuation is stretched (P/E ~46.7) given compressed margins. Earnings-call commentary is moderately positive on strategy and guidance, tempered by higher acquisition costs, SG&A pressure, and retail execution/cadence risks.
Positive Factors
Balance Sheet Strength
Very low leverage and ample equity provide durable financial flexibility. This conservatively financed balance sheet lets the company absorb cash volatility, fund omnichannel rollouts or retail inventories without near-term refinancing risk, and sustain investments over the next several quarters.
Negative Factors
Compressed Profitability
Net margin compression materially reduces retained earnings and sensitivity to SG&A or marketing increases. Even with strong gross margins, diminished bottom-line profitability constrains the firm's ability to fund expansion or absorb setbacks without further margin improvement or cost reduction.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Very low leverage and ample equity provide durable financial flexibility. This conservatively financed balance sheet lets the company absorb cash volatility, fund omnichannel rollouts or retail inventories without near-term refinancing risk, and sustain investments over the next several quarters.
Read all positive factors
USANA Health (USNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$408.22M
Dividend YieldN/A
Average Volume (3M)173.43K
Price to Earnings (P/E)46.7
Beta (1Y)1.12
Revenue Growth5.67%
EPS Growth-73.96%
CountryUS
Employees1,570
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)0.47
Shares Outstanding18,463,010
10 Day Avg. Volume170,208
30 Day Avg. Volume173,431
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)0.68
Price to Sales (P/S)0.39
P/FCF Ratio42.35
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.12
Revenue Forecast (FY)$938.74M
USANA Health Business Overview & Revenue Model
Company Description
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer....
How the Company Makes Money
USANA primarily makes money by selling its health and personal care products through a multi-level/direct-selling model. The company recognizes revenue mainly from product sales to its independent distributors/associates (who purchase for personal...
USANA Health Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 27, 2026
Earnings Call Sentiment Neutral
The call balanced clear strategic progress (strong balance sheet, stable core nutrition, successful new product launches, and retail expansion for Hiya and Rise) with meaningful near-term operational and financial headwinds (a $29M goodwill impairment for Hiya, a quarterly pre-tax loss with a $9M tax charge, lowered full-year outlook, Hiya DTC marketing pressures, and a Rise packaging disruption). Management emphasized long-term conviction and the ability to invest, but acknowledged near-term impacts to revenue, margins, and tax rates.Positive Updates
Strong Balance Sheet and Cash Generation
Ended the quarter with $169 million in cash, zero debt, and generated $20 million of free cash flow, providing financial flexibility to invest in growth and venture brands.
Negative Updates
Hiya Goodwill Impairment Charge
Recorded a preliminary non-cash goodwill impairment of $29 million related to the Hiya reporting unit due to lower-than-expected near-term performance and updated valuation assumptions.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Balance Sheet and Cash Generation
Ended the quarter with $169 million in cash, zero debt, and generated $20 million of free cash flow, providing financial flexibility to invest in growth and venture brands.
Read all positive updates
Company Guidance
Management lowered its fiscal 2026 outlook — citing a tougher direct‑to‑consumer digital marketing environment for Hiya and a packaging disruption at Rise Wellness — and now expects Hiya full‑year net sales to be lower than previously anticipated and near‑term net sales at Rise to be reduced; the quarter included a preliminary non‑cash goodwill impairment charge of $29.0 million related to Hiya and a $9.0 million income tax expense on a $19.0 million pre‑tax loss, management said the update reflects roughly a $30–40 million top‑line swing versus prior expectations with about $4–5 million of margin pressure, and they noted an elevated tax rate for the back half of the year despite a strong balance sheet of $169.0 million in cash, zero debt, $20.0 million of free cash flow this quarter, Hiya’s historical advertising spend of about $150.0 million, and Rise’s planned retail footprint of over 4,000 doors by year‑end.USANA Health Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
84
Very Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 925.94M | 925.26M | 854.50M | 921.01M | 998.60M | 1.19B |
| Gross Profit | 710.35M | 724.40M | 678.75M | 731.62M | 791.32M | 955.53M |
| EBITDA | 80.17M | 82.07M | 98.86M | 123.11M | 130.22M | 192.89M |
| Net Income | 8.87M | 10.76M | 42.03M | 63.79M | 69.35M | 116.50M |
Balance Sheet | ||||||
| Total Assets | 738.97M | 742.91M | 748.19M | 632.76M | 596.55M | 577.74M |
| Cash, Cash Equivalents and Short-Term Investments | 162.75M | 158.38M | 181.77M | 330.42M | 288.42M | 239.83M |
| Total Debt | 14.00M | 14.00M | 39.20M | 13.21M | 13.78M | 17.30M |
| Total Liabilities | 144.18M | 156.64M | 161.86M | 135.56M | 162.08M | 182.62M |
| Stockholders Equity | 543.55M | 533.10M | 532.11M | 497.20M | 434.47M | 395.12M |
Cash Flow | ||||||
| Free Cash Flow | 2.96M | 8.53M | 50.92M | 56.15M | 93.50M | 108.46M |
| Operating Cash Flow | 16.63M | 22.35M | 60.99M | 70.64M | 103.90M | 121.23M |
| Investing Cash Flow | -8.85M | -10.13M | -213.09M | -11.97M | -12.37M | -14.19M |
| Financing Cash Flow | -29.78M | -40.60M | 9.55M | -14.24M | -30.09M | -181.41M |
USANA Health Technical Analysis
Positive
22.84
Price Trends
20.52
Positive
19.37
Positive
19.82
Positive
Market Momentum
0.55
Positive
58.02
Neutral
67.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USNA, the sentiment is Positive. The current price of 22.84 is above the 20-day moving average (MA) of 22.12, above the 50-day MA of 20.52, and above the 200-day MA of 19.82, indicating a bullish trend. The MACD of 0.55 indicates Positive momentum. The RSI at 58.02 is Neutral, neither overbought nor oversold. The STOCH value of 67.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for USNA.
USANA Health Risk Analysis
USANA Health disclosed 43 risk factors in its most recent earnings report. USANA Health reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
USANA Health Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $455.09M | 30.08 | 17.76% | ― | 21.85% | 44.53% | |
68 Neutral | $354.34M | 18.15 | 12.30% | ― | 7.26% | 104.70% | |
65 Neutral | $93.07M | 15.48 | 14.03% | ― | 42.27% | -33.19% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | $408.22M | 46.74 | -4.15% | ― | 5.67% | -73.96% | |
60 Neutral | $1.29B | 5.33 | -43.03% | ― | 3.69% | -16.34% | |
60 Neutral | $81.12M | 13.92 | 17.78% | 2.90% | -12.15% | -38.04% |
* Consumer Defensive Sector Average
USNA
USANA Health
22.78
-6.26
-21.56%
HLF
Herbalife
12.80
3.55
38.38%
LWAY
Lifeway Foods
29.35
1.69
6.11%
NATR
Nature's Sunshine Products
20.46
5.06
32.86%
LFVN
LifeVantage
6.83
-5.77
-45.80%
FTLF
FitLife Brands
9.84
-5.10
-34.14%
USANA Health Corporate Events
Business Operations and StrategyFinancial Disclosures
USANA Health Cuts Outlook After Impairment-Driven Quarterly Loss
Negative
Aug 4, 2026
USANA Health Sciences reported that for the fiscal second quarter ended July 4, 2026, net sales fell 5% year over year to $223 million and the company swung to a net loss of $21.4 million, driven by a $29.1 million non-cash impairment charge. Adju...
Executive/Board ChangesShareholder Meetings
USANA Shareholders Approve Directors, Auditor and Compensation
Positive
May 20, 2026
At its Annual Meeting of Shareholders on May 20, 2026, USANA Health reported that approximately 89% of its outstanding common shares were represented in person or by proxy, demonstrating strong investor participation. Shareholders elected eight di...
Business Operations and StrategyFinancial Disclosures
USANA Health Q1 2026 Results Highlight Mixed Performance
Negative
May 5, 2026
USANA Health Sciences reported flat first-quarter 2026 net sales of $250 million versus a year earlier, but net earnings fell 20% to $7.5 million and diluted EPS declined to $0.41, reflecting margin and customer pressures across core operations. C...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.